Novel lactic acid bacteria and use thereof

{
  "publication_number": "US2026102442A1",
  "country": "US",
  "kind": "A1",
  "title": "Novel lactic acid bacteria and use thereof",
  "abstract": "The present invention relates to a novel lactic acid bacterium, and more particularly, to a composition comprising Lactobacillus reuteri NK33 (KCCM12090P) or Bifidobacterium adolescentis NK98 (KCCM12297P), which is the novel lactic acid bacterium, useful in preventing and treating a neurological mental disease or an inflammatory disease. Also, the present invention relates to a composition for diagnosing a neurological mental disease, comprising a preparation for measuring a level of an intestinal microorganism, a kit comprising the same, and a method for diagnosing the neurological mental disease, comprising a step of measuring the level of the intestinal microorganism.",
  "claims": [
    "1. A method for treating a mental disorder or an inflammatory disease, comprising: administering Bifidobacterium adolescentis NK98 (KCCM12297P) into a subject, wherein the inflammatory disease is colitis, and wherein the mental disorder is one or more selected from the group consist of anxiety, depression, insomnia, and stress. 2. The method according to claim 1, wherein the mental disorder is insomnia. 3. The method according to claim 1, wherein the Bifidobacterium adolescentis NK98 (KCCM12297P) comprises a 16S rDNA sequence of SEQ ID NO: 38. 4. The method according to claim 1, wherein the Bifidobacterium adolescentis NK98 (KCCM12297P) is a live bacterial cell thereof, a dead bacterial cell thereof, a culture product thereof or a crushed product thereof. 5. A method for alleviating a mental disorder comprising: administering Bifidobacterium adolescentis NK98 (KCCM12297P) and Lactobacillus reuteri NK33 (KCCM12090P) into a subject, wherein the mental disorder is insomnia. 6. The method according to claim 5, wherein the Bifidobacterium adolescentis NK98 (KCCM12297P) comprises a 16S rDNA sequence of SEQ ID NO: 38. 7. The method according to claim 5, wherein the Lactobacillus reuteri NK33 (KCCM12090P) comprises a 16S rDNA sequence of SEQ ID NO: 1. 8. The method according to claim 5, wherein the Bifidobacterium adolescentis NK98 (KCCM12297P) comprises a 16S rDNA sequence of SEQ ID NO: 38, and the Lactobacillus reuteri NK33 (KCCM12090P) comprises a 16S rDNA sequence of SEQ ID NO: 1. 9. The method according to claim 5, wherein the Bifidobacterium adolescentis NK98 (KCCM12297P) and the Lactobacillus reuteri NK33 (KCCM12090P) are, respectively, a live bacterial cell thereof, a dead bacterial cell thereof, a culture product thereof or a crushed product thereof."
  ],
  "description_excerpt": "The present invention relates to Lactobacillus reuteri and Bifidobacterium adolescentis, which are novel lactic acid bacteria, and more particularly, to a composition comprising the novel lactic acid bacteria useful in preventing and treating a neurological mental disease or an inflammatory disease.\n\nAlso, the present invention relates to a composition for diagnosing the neurological mental disease, comprising a preparation for measuring a level of an intestinal microorganism.\n\nIn modern society, neurological mental diseases including anxiety, depression, schizophrenia, etc. are on the increase due to a rapid rise in stress, etc. In particular, the trend is that more and more patients are suffering from mental disorders such as depression, anxiety and the like due to various causes such as social and structural ones, etc. in our modern times overflowing with individualism.\n\nIn severe cases, patients with mental disorders may end up committing suicide accidents. In particular, it is reported that more than half of depressed patients consider suicide. Indeed, it is known that 10 to 15% of those patients actually commit suicide.\n\nMental disorders have no clear and objective criteria for judgment yet, such that symptoms thereof may vary depending on respective patients. If there is any suspicion about mental disorders, treatment is required according to accurate diagnosis and examination. However, the reality is that such proper treatment is not done due to negative social attitudes toward hospital treatments for mental disorders. Also, drugs such as antidepressants, etc.",
  "cpc": [
    "A61K 35/747",
    "A23L 33/135",
    "A61K 35/745",
    "C12N 1/205"
  ],
  "assignees": [
    "Kyung Hee University",
    "Navipharm Co Ltd"
  ],
  "inventors": [
    "Dong-Hyun Kim",
    "Myung Joo Han"
  ],
  "filing_date": "2025-09-25",
  "publication_date": "2026-04-16",
  "priority_date": "2017-09-29",
  "application_number": "US-202519340623-A",
  "cited_by_count": 0
}